Ian F. Smith

Ian F. Smith is the interim chief executive officer of Stoke Therapeutics and he has served as a member of Stoke Therapeutics’ Board of Directors since September 2023. With more than 20 years of finance and operations experience and extensive relationships in the industry, Mr. Smith is a biotechnology leader who has spent most of his career focused on delivering life-changing medicines to patients with rare diseases. He currently serves as a senior advisor to Bain Capital Life Sciences, a position he has held since January 2021, and provides other advisory and consulting services to life science companies. He also sits on the Board of Directors for Rivus Pharmaceutical, Foghorn Therapeutics, Solid Biosciences, Alkeus Pharmaceuticals, iVexSol and Odyssey Therapeutics. He previously served as Executive Vice President and Chief Operating Officer, and Chief Financial Officer of Vertex Pharmaceuticals between 2001 and 2019. Prior to 2001, Mr. Smith was a partner in the Life Science and Technology Practice of the accounting firm Ernst & Young LLP. He holds a B.A. with honors in accounting and finance from Manchester Metropolitan University (UK).